Holen Sie sich die Stockscreener-App
1.54
3.14%
-0.05
Handel nachbörslich:
1.54
Schlusskurs vom Vortag:
$1.59
Offen:
$1.62
24-Stunden-Volumen:
3.91M
Relative Volume:
0.92
Marktkapitalisierung:
$408.32M
Einnahmen:
$194.75M
Nettoeinkommen (Verlust:
$-51.26M
KGV:
-5.50
EPS:
-0.28
Netto-Cashflow:
$-23.38M
1W Leistung:
-12.50%
1M Leistung:
-51.27%
6M Leistung:
-47.26%
1J Leistung:
-13.97%
1-Tages-Spanne:
$1.525
$1.6555
1-Wochen-Bereich:
$1.525
$1.835
52-Wochen-Spanne:
$1.52
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Firmenname
Akebia Therapeutics Inc
Sektor
Telefon
617-871-2098
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie AKBA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.54 | 421.93M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
115.89 | 51.60B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.51B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.60 | 42.35B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
24.28 | 28.04B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
474.72 | 20.52B | 3.08B | 1.24B | 1.07B | 25.61 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-28 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-01 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-31 | Herabstufung | Needham | Buy → Hold |
| 2022-03-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Bestätigt | Needham | Buy |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-11 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2019-03-20 | Eingeleitet | Citigroup | Neutral |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-06-06 | Bestätigt | H.C. Wainwright | Buy |
| 2017-12-19 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-12-07 | Eingeleitet | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | Needham | Buy |
| 2016-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2016-12-20 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-15 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-29 | Eingeleitet | Brean Capital | Buy |
| 2016-03-16 | Bestätigt | Needham | Buy |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
How forex fluctuations impact Akebia Therapeutics Inc. (AX9) stockWeekly Loss Report & Reliable Intraday Trade Plans - newser.com
How Akebia Therapeutics Inc. stock compares to market leadersPortfolio Risk Summary & Growth Focused Entry Point Reports - newser.com
What analyst consensus implies for Akebia Therapeutics Inc. (AX9) stockCEO Change & AI Forecasted Entry/Exit Points - newser.com
Is Akebia Therapeutics Inc. stock cheap at current valuationBond Market & Weekly High Potential Stock Alerts - newser.com
Live market analysis of Akebia Therapeutics Inc.Portfolio Gains Report & Real-Time Sentiment Analysis - newser.com
How Akebia Therapeutics Inc. (AX9) stock gains from tech spendingTrade Entry Report & Free Verified High Yield Trade Plans - newser.com
How Akebia Therapeutics Inc. (AX9) stock behaves in tightening cyclesMarket Volume Summary & Expert Curated Trade Setups - newser.com
Signal strength of Akebia Therapeutics Inc. stock in tech scannersJuly 2025 Opening Moves & Low Risk Entry Point Guides - newser.com
Is Akebia Therapeutics Inc. stock a safe investment in uncertain markets2025 AllTime Highs & Low Drawdown Investment Strategies - newser.com
How strong dollar benefits Akebia Therapeutics Inc. (AX9) stock - newser.com
Tools to assess Akebia Therapeutics Inc.’s risk profileJuly 2025 Weekly Recap & Stock Portfolio Risk Control - newser.com
Brokerages Set Akebia Therapeutics, Inc. (NASDAQ:AKBA) Price Target at $6.00 - Defense World
This trade activity should not be overlooked: Akebia Therapeutics Inc (AKBA) - Setenews
Levi & Korsinsky Announces an Investigation on Behalf of Akebia Therapeutics, Inc. (AKBA) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
AKBA: Vafseo's expanding access and strong clinical data position it for standard of care in dialysis - TradingView
Akebia Therapeutics, Inc. Announces Amendment to License Agreement for Drug Supply and Manufacturing Rights - MarketScreener
Akebia Therapeutics amends license agreement with Medice for Vafseo supply - Investing.com
Akebia Therapeutics amends license agreement with Medice for Vafseo supply By Investing.com - Investing.com South Africa
Akebia Therapeutics Inc says on Nov 12, co and Medice amend license agreement - MarketScreener
Analyzing Akebia Therapeutics Inc. with risk reward ratio charts2025 Trading Recap & Reliable Breakout Stock Forecasts - newser.com
Akebia Therapeutics Shares Extend Decline Amid Analyst Downgrades - Ad-hoc-news.de
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
FY2025 Earnings Forecast for AKBA Issued By Leerink Partnrs - MarketBeat
Akebia Therapeutics Inc. stock retracement – recovery analysisMarket Performance Recap & Growth Oriented Trading Recommendations - newser.com
Shareholders Alert: Investigation Into Akebia Therapeutics, Inc. (AKBA)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
How Akebia Therapeutics Inc. stock reacts to job market data2025 Price Targets & Community Consensus Picks - newser.com
Why Akebia Therapeutics Inc. (AX9) stock attracts wealthy investorsExit Point & AI Driven Price Predictions - newser.com
How rising interest rates impact Akebia Therapeutics Inc. stockQuarterly Profit Report & Accurate Technical Buy Alerts - newser.com
Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.17%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):